Vor Bio Presents 48-Week Phase 3 Myasthenia Gravis Data
Telitacicept delivered a placebo‑adjusted 4.83‑point improvement on MG‑ADL at 24 weeks in a Phase 3 study of generalized myasthenia...
Sarcoidosis Foundation Reacts to Atyr Phase 3 Trial Results
In a 268‑patient Phase 3 trial spanning the U.S., Europe, Japan, and Brazil, efzofitimod did not meet its primary...
Cariprazine Depot Phase I/II Study Recruits First Patient
Mapi Pharma has enrolled the first patient in a multinational Phase I/II study of its once-monthly injectable cariprazine for...
Hyperbaric Oxygen Therapy Shows Promise for Long-Term PTSD
In a reanalysis of a prior trial in 56 male veterans with treatment‑resistant PTSD, participants who achieved at least...
World’s First Self-Regulating Immunotherapy Trial Launches
The UK’s MHRA has granted Clinical Trial Authorisation for NVG-222, clearing a first-in-human, Phase I/II adaptive basket study in...
Tonix Licenses Phase 2/3-Ready Antibody for Lyme Prevention
Phase 1 data for TNX-4800 (mAb 2217LS) showed safety and tolerability with a linear pharmacokinetic:pharmacodynamic: efficacy relationship, supporting dose...
Landmark Vivos Trial Treats Pediatric Obstructive Sleep Apnea
A multicenter pediatric trial of Vivos Therapeutics’ DNA (Daytime-Nighttime Appliance) reported that 77% of participants achieved at least a...
Rein Therapeutics Publishes Novel IPF Therapy Data in iScience
Ex vivo human IPF lung slices exposed to LTI-03 showed reductions across TGFβ, VEGF, PDGF, and FGF signaling, along...
Hope for AMD: Kalaris Enrolling New Phase 1/2 Drug Trial
No efficacy or safety data were released. Kalaris has begun enrolling a Phase 1b/2 multiple ascending dose study of...
First Real-World Study Reveals Patient Experience on Sympazan
In a retrospective EHR cohort spanning 2015–2024, Stanford Health Care identified 181 patients with epilepsy treated with clobazam oral...